S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective
Send us a text Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Louise Campbell raises two very different points about the earlier conversation. Louise's first point has to do with steps taken to maintain compliance with clinical trials and whether researchers can analyze these in a way that will help front-line treaters understand what are keys to patient pharmaco-adherence. This leads to a ...
3 Okt 202113min
S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"
Send us a text Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison starts by discussing some issues and insights around the use of FGF-21s and then "hijacks" the conversation to explore a standard practice in histopathology that he would like to change. This conversation starts with Stephen talking about the differences between FGF-21s and discussing why these results are so com...
2 Okt 202112min
S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things
Send us a text Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison provides an image to suggest the enormity of the coming NASH pandemic and Mazen identifies his two biggest stories of summer. Mazen's "biggest things of summer" include Stephen's recent article on the efruxifermin Phase 2a trial that was published in Nature and the Mayo Clinic group's work on MRE. For the efruxif...
2 Okt 202111min
S2-E48 - Closing Thoughts On an Eventful NASH Summer
Send us a text Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer" with his own unique slant on recent events and publications. Mazen's take on the 'Biggest Stories of NASH Summer" integrates the content of papers, the journals in which they were published and the attention they received to form a message that says, "Fatty Liver has more good news to report and more people who want to learn about it." Halfway through,...
30 Sep 202150min
S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"
Send us a text Professor Manal Abdelmalek joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on NIH's recent decision to stand up and fund the Liver Cirrhosis Network. To Dr Abdelmalek, the NIH action signifies increased focus on the significant long-term consequences of Fatty Liver disease. She discusses a Q&A at a talk she gave this summer where a physician noted that drug development is exciting but three years in the...
26 Sep 202127min
S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."
Send us a text Professor and epidemiologist Michelle Long joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on the recent paper on prevalence of NAFLD and NASH in an unselected middle-aged population. To Dr. Long, an epidemiologist, there has been very little high quality perspective research on NAFLD/NASH prevalence. She discusses why she considers the study a methodological advantage. She and Roger Green agree that the co...
25 Sep 202122min
S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."
Send us a text Newly-appointed Professor Ian Rowe joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. He focuses on the recent FDA approval of the ELF test for prognosis of cirrhosis. To Professor Rowe, the ELF approval was the most important story of summer because it promises a brighter future for non-invasive tests and, eventually, decreased reliance on biopsy. Dr. Rowe points out that transitioning from the ordinal results that biopsy...
25 Sep 202122min
S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer
Send us a text Ian Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer. Which NAFLD/NASH stories did they choose? The newly-appointed Professor Rowe discusses the importance of the FDA approval of the ELF test as a prognostic for cirrhosis. True to her epidemiological background, Professor Long reviews the prospective prevalence study that Stephen Harrison, Naim Alkhouri and others conducted in San Antonio. Finally, Professor Abde...
24 Sep 20211h 13min
